GlassScriptPhysician profile
Mark M Boiskin
NPI 1437154143
$4,469.21
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $556 · 2021: $196 · 2022: $1,459 · 2023: $13.60 · 2024: $1,746 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,633 · Food and Beverage: $360 · Education: $15.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,633.32 |
| Food and Beverage | $359.91 |
| Education | $15.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,745.95 | 2024 | |
| Merck Sharp & Dohme LLC | $908.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $393.73 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $357.17 | 2019-2020 | |
| Vifor Pharma, INC. | $253.25 | 2019-2022 | |
| Nxstage Medical, INC. | $168.71 | 2022-2025 | Liberty Select Cycler, Nxstage System One |
| Amgen INC. | $96.95 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $76.79 | 2020-2022 | |
| Ardelyx, INC. | $67.34 | 2025 | Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $61.75 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $56.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.49 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $55.61 | 2021-2022 | |
| Akebia Therapeutics INC | $51.70 | 2019 | |
| Kyowa Kirin, INC. | $50.00 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.85 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $15.57 | 2022 | |
| Boston Scientific Corporation | $14.09 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Boiskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.